Header Logo

Connection

Melody Cobleigh to Antibodies, Monoclonal, Humanized

This is a "connection" page, showing publications Melody Cobleigh has written about Antibodies, Monoclonal, Humanized.
  1. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
    View in: PubMed
    Score: 0.111
  2. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410.
    View in: PubMed
    Score: 0.110
  3. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21.
    View in: PubMed
    Score: 0.106
  4. A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.
    View in: PubMed
    Score: 0.053
  5. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24.
    View in: PubMed
    Score: 0.052
  6. Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
    View in: PubMed
    Score: 0.052
  7. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
    View in: PubMed
    Score: 0.025
  8. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
    View in: PubMed
    Score: 0.022
  9. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8.
    View in: PubMed
    Score: 0.019
  10. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
    View in: PubMed
    Score: 0.018
  11. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
    View in: PubMed
    Score: 0.016
  12. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
    View in: PubMed
    Score: 0.015
  13. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
    View in: PubMed
    Score: 0.014
  14. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
    View in: PubMed
    Score: 0.014
  15. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
    View in: PubMed
    Score: 0.012
  16. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
    View in: PubMed
    Score: 0.011
  17. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.